선택지 정리됨
부신피질암: 국가별 치료 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨고형암최종 확인 2026.06
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Mitotane (Lysodren)[1]FDA-approvedFunctional versus nonfunctional hormonal status is clinically relevant; no genomic biomarker required by fetched U.S. label; Inoperable functional or nonfunctional ACC. · Label indication does not establish payer coverage, treatment suitability, or dosing for a specific patient. Label includes major safety updates and monitoring/handling precautions. Confidence/conflicts: High for U.S. labeled indication.
European Union
- Mitotane (Lysodren)[2]EMA authorisedFunctional hormone-producing status affects symptom benefit; no genomic biomarker required by fetched EMA source; Advanced unresectable, metastatic, or relapsed ACC; symptom treatment context per EMA wording. · EMA central authorisation does not establish member-state reimbursement, local specialist access, or individual eligibility. EMA notes limited evidence for some uses and the need for blood-level monitoring. Confidence/conflicts: High for EU authorised indication; national reimbursement remains unverified.
United Kingdom
- Mitotane (Lysodren), alone or with other chemotherapy drugs[3]ApprovedNo biomarker required by fetched UK source; Unresectable, relapsed, or metastatic ACC. · Cancer Research UK is a patient/professional cancer information charity, not MHRA/NICE. Exact UK licensing, commissioning, and local formulary status require separate regulator/NHS source verification. Confidence/conflicts: Medium-high for UK treatment-information context; exact MHRA/NICE status remains an active gap.
출처
- DailyMed / U.S. FDA label — official drug label · official drug label
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- Cancer Research UK — UK cancer information / drug information · UK cancer information / drug information
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026.06.
승인된 치료 너머
임상시험 및 신흥 선택지
환자가 거주하는 국가에서 아직 승인된 표준 치료가 아닌 선택지입니다 — 연구, 임상시험, 허가 외 사용, 담당 종양내과 의사가 먼저 언급하지 않을 수 있는 초기 근거입니다. 각 항목은 근거의 강도에 따라 구분됩니다. 여기에 실린 항목은 조사하고 의료진과 상의할 정보일 뿐, 효과가 입증되었거나 안전하거나 현재 이용 가능하다는 의미가 아닙니다. 임상 세부 내용은 영문이 정본입니다.
임상시험 진행 중
- Complete surgical removal; adjuvant mitotane under clinical evaluation; radiation therapy for selected unresectable/localized or metastatic sites; mitotane; mitotane plus streptozotocin or mitotane plus etoposide/doxorubicin/cisplatin; antisteroidogenic drugs for hormone excess; clinical trials임상시험임상시험InvestigationalUnited States · No biomarker required by fetched NCI PDQ source; Stage I-II localized ACC, stage III locally advanced ACC, stage IV metastatic ACC, recurrent ACC, hormone-producing ACC symptom control. · NCI PDQ is an evidence summary and not a formal guideline, payer, or regulator source. Adjuvant mitotane and several radiation/systemic approaches are described as under clinical evaluation. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific mitotane indication recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
- Osilodrostat임상시험 · NCT02468193임상시험Trial only (registry)Japan · Hormone-producing Cushing syndrome context; no genomic biomarker required by fetched registry record; Cushing syndrome and related adrenal disease context including adrenal carcinoma. · This is not an ACC-directed anticancer trial; it is a hormonal/symptom-control context that includes adrenal carcinoma. Registry listing does not establish PMDA approval, reimbursement, routine access, or individual eligibility. Confidence/conflicts: Medium for Japan ACC-related supportive/hormonal trial context; low for Japan tumor-directed ACC treatment availability. ClinicalTrials.gov — clinical-trial registry
- Pembrolizumab plus lenvatinib; real-world adrenal disease registry/cohort management studies임상시험 · NCT05036434임상시험Trial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced adrenal cortical carcinoma for pembrolizumab/lenvatinib; adrenal disease evidence-generation/cohort contexts including ACC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Observational adrenal disease records are not treatment access records. Confidence/conflicts: Medium-high for Korea registry-listed ACC trial/cohort activity; routine access unverified. ClinicalTrials.gov — clinical-trial registry
- Camrelizumab plus apatinib plus mitotane; adjuvant radiotherapy versus observation; camrelizumab plus apatinib second-line; individualized mRNA neoantigen vaccine (mRNA-0523-L001); triprolizumab plus radiotherapy; China adrenal disease registry임상시험 · NCT06831175임상시험Trial only (registry)China · Individualized mRNA neoantigen vaccine study implies tumor-specific neoantigen selection; no other biomarker required by fetched China registry records; Advanced ACC; high-risk localized ACC after surgery; recurrent/metastatic ACC; advanced endocrine tumor including ACC. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. Some records are registry or not-yet-recruiting rather than treatment access. Confidence/conflicts: High for China registry-listed ACC trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
임상시험이나 초기 보고에 실렸다는 것은 해당 선택지가 연구되고 있다는 의미일 뿐, 효과가 있거나 특정 환자에게 안전하거나 현재 등록 가능하다는 뜻은 아닙니다. 어떤 선택지가 적합한지는 담당 종양내과 팀과 임상시험 팀이 함께 상의할 문제입니다. 최종 확인 2026.06.
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- Is complete surgical resection feasible at an ACC-experienced center?
- Is mitotane being discussed as adjuvant, unresectable, metastatic, or symptom-control therapy?
- Are hormone-producing symptoms being managed alongside cancer-directed treatment?
- Is the ACC inoperable, functional, or nonfunctional under the U.S. label indication?